Aviado · Research
Longevity Daily
Friday, November 6, 2026
Listen
Today's Brief
Today's strongest story is a 5-year MRI study showing lifetime estrogen exposure cuts cerebral small vessel disease by up to 59% — landmark data for any woman weighing HRT decisions. In supplements, a University of Surrey RCT confirms NOVOS Core's vascular benefits, while ConsumerLab raises a red flag on long-term NMN use and kidney health. Aviado's latest deep-dive maps how NAC lowers IL-6 and CRP at the molecular level. And a sweeping analysis of 51 longitudinal studies names metformin and semaglutide as the most potent epigenetic age-reversers on record.
10 stories4 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Lifetime Estrogen Exposure Cuts Brain Vessel Disease by Up to 59%, 5-Year MRI Study Finds
A 5-year MRI study published in Neurology found that women with longer reproductive lifespans and those who used hormone therapy had up to 59% lower cerebral small vessel disease burden — one of the most significant drivers of age-related cognitive decline. The research tracked white matter integrity across a large cohort, directly linking lifetime estrogen exposure to healthier brain microvasculature. For women navigating HRT decisions, this is among the most concrete brain-imaging evidence to date that estrogen actively protects the brain's smallest blood vessels, not just menopause symptoms. Women with earlier menopause or no HRT showed meaningfully worse outcomes, suggesting the perimenopausal window is a critical moment for brain health strategy.
Read more →Brain Scans Can Predict Alzheimer's Risk Years Before Memory Loss or Plaques Appear
Stanford Medicine researchers developed a resting-state fMRI measure that identifies brain firing patterns linked to Alzheimer's vulnerability in cognitively normal adults — before memory problems or plaques accumulate, with findings published in Science Advances. The implication is a potential screening tool that could flag risk years or even decades before any clinical sign emerges. This is early-stage research requiring broader validation, but it moves the field meaningfully closer to truly preventive intervention in asymptomatic individuals.
Read more →Supplements & Compounds
NOVOS Core Supplement Cuts Blood Pressure by 6 mmHg and Improves Arterial Stiffness in 6-Month RCT
A 6-month placebo-controlled RCT led by the University of Surrey found that NOVOS Core — a multi-ingredient supplement targeting multiple aging hallmarks — reduced systolic blood pressure by 6.1 mmHg, improved endothelial function, and reduced arterial stiffness in adults around age 60. Notably, endothelial improvements were detectable within just 1 hour of the first dose. Blood lipids including cholesterol were unchanged, suggesting the vascular effect is specific rather than broadly metabolic — a meaningful distinction for longevity-oriented supplement users.
Read more →Long-Term NMN Supplementation May Cause Kidney Injury in Older Adults, New Lab Research Warns
ConsumerLab's latest analysis flags new laboratory research suggesting that long-term NMN supplementation might cause kidney injury in older people — a significant caveat for the growing number of daily NMN users in the longevity community. This is laboratory research, not a human clinical trial, so it does not prove harm. But if you're taking NMN consistently, it's worth checking kidney function markers and discussing with a physician, particularly if you have any baseline renal concerns.
Read more →NAC Replenishes Glutathione to Reduce Inflammatory Cytokines: What the Evidence Actually Shows
NAC works as both a direct glutathione precursor and an independent modulator of key inflammatory markers — IL-6, IL-8, and CRP — with consistent reductions confirmed across meta-analyses of randomized controlled trials. The evidence for IL-6 reduction is the most robust, though the magnitude varies by population and clinical context, typically at daily doses of 600–1,200 mg. This mechanistic clarity helps explain why NAC's anti-inflammatory reputation holds up under scrutiny, even as the supplement industry tends to oversell the effect size.
Read the full Aviado analysis →Research & Papers
Metformin and Semaglutide Top 51-Study Analysis as the Most Potent Epigenetic Age-Reversers
An analysis spanning 51 longitudinal studies and more than 110 DNA methylation biomarkers found that metformin, semaglutide, and anti-TNF treatments produced the largest measurable drops in biological age across 16 epigenetic clocks — outperforming most lifestyle interventions in head-to-head comparisons. Diet and exercise also moved the clocks in the right direction, but drug-driven reductions were notably larger in magnitude. This is observational data with heterogeneity across studies, but the consistency across 16 independent clocks makes the signal hard to dismiss.
Read more →Four Weeks of Low-Dose Rapamycin Improved Brain Blood Flow in APOE4 Carriers
A University of Missouri pilot study found that just four weeks of low-dose rapamycin improved cerebral blood flow in healthy middle-aged adults carrying the APOE4 gene variant — the most common genetic risk factor for Alzheimer's disease. The sample size was small and results are preliminary, but the finding adds to growing evidence that rapamycin may have a role in preventive neurology beyond its established longevity pharmacology. APOE4 carriers face 3–4x elevated Alzheimer's risk and have very few prevention options today, making this worth watching in larger trials.
Read more →Lifestyle & Nutrition
Scientists Are Rethinking What Menopause Does to the Brain — And the Answer Is More Serious Than You Think
New evidence is reshaping how scientists understand menopause's effect on the brain: estrogen appears to function as neuroprotective armor, and its withdrawal during perimenopause may open a window of elevated cognitive vulnerability rather than simply causing temporary symptoms. This Fast Company feature synthesizes emerging research showing the hormonal shift removes a key biological buffer for brain health, with particular implications for white matter and microvascular integrity. The practical takeaway: brain fog and mood changes around menopause may be early neurobiological signals worth taking seriously — and acting on early.
Read more →WHO Issues New Dementia Guidelines: Risk Reduction Should Start in the Doctor's Office, Not the Memory Clinic
New WHO guidelines on dementia prevention, published in Nature Reviews Neurology, call for a proactive, lifelong approach to cognitive decline risk reduction — placing clinicians at the center of identifying and managing modifiable factors like blood pressure, physical activity, diet, and social engagement. The guidance pushes back against single-fix thinking, emphasizing that multidomain interventions tailored to individual risk profiles are what the evidence supports. This marks a significant reframing: dementia prevention is a primary care priority starting decades before symptoms, not a late-life specialty referral.
Read more →Industry & Policy
Insilico Opens Its AI Longevity Platform to the World — and Drops Phase IIa Data Showing Biological Age Reversal
Insilico Medicine has open-sourced a 24/7 personal longevity AI platform — including LongevityBench and Longevity-LLMs — while simultaneously reporting Phase IIa clinical data showing its lead drug candidate reversed biological age across six independent proteomic aging clocks, published in Nature Biotechnology. The combination of open-source research infrastructure and positive clinical-stage human data is a rarity in longevity biotech, where most companies are still running pre-clinical programs. Worth watching: whether the aging clock reversal translates to tangible health outcomes in longer-term follow-up.
Read more →